Advertisement

Topics

Psychosis - Pipeline Review, H1 2015

05:01 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Psychosis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 52-page report is available in PDF from $2000.

Psychosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Psychosis - Pipeline Review, H1 2015’, provides an overview of the Psychosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Psychosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Psychosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Psychosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Psychosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Psychosis Overview 6
Therapeutics Development 7
Pipeline Products for Psychosis - Overview 7
Pipeline Products for Psychosis - Comparative Analysis 8
Psychosis - Therapeutics under Development by Companies 9
Psychosis - Therapeutics under Investigation by Universities/Institutes 10
Psychosis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Psychosis - Products under Development by Companies 15
Psychosis - Products under Investigation by Universities/Institutes 16
Psychosis - Companies Involved in Therapeutics Development 17
Acadia Pharmaceuticals Inc. 17
Evotec AG 18
Heptares Therapeutics Ltd. 19
Newron Pharmaceuticals S.p.A. 20
Reviva Pharmaceuticals Inc. 21
Sumitomo Dainippon Pharma Co., Ltd. 22
Psychosis - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 29
Drug Profiles 30
Drug to Agonize Muscarinic M1/M4 Receptors for Psychosis and Cognitive Impairment - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Drug to Agonize Muscarinic M4 Receptors for Psychosis - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NW-3509 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
pimavanserin tartrate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
RP-5063 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Inhibit PDE10a for Schizophrenia and Psychosis - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Activate Sigma Receptor for CNS Disorders - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Psychosis - Recent Pipeline Updates 39
Psychosis - Dormant Projects 45
Psychosis - Discontinued Products 46
Psychosis - Product Development Milestones 47
Featured News & Press Releases 47
Nov 17, 2014: Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch 47
Sep 02, 2014: Acadia Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis 47
Aug 28, 2014: ACADIA Pharmaceuticals Announces Trade Name NUPLAZID for Pimavanserin 48
Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of…

For more information open Psychosis - Pipeline Review, H1 2015.

SKU: GMDHC6628IDB

Original Article: Psychosis - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Psychosis - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...